Logo image of XGN

EXAGEN INC (XGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XGN - US30068X1037 - Common Stock

5.95 USD
-0.09 (-1.49%)
Last: 1/5/2026, 8:00:02 PM
5.95 USD
0 (0%)
After Hours: 1/5/2026, 8:00:02 PM
Fundamental Rating

2

XGN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. XGN may be in some trouble as it scores bad on both profitability and health. XGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XGN has reported negative net income.
XGN had a negative operating cash flow in the past year.
XGN had negative earnings in each of the past 5 years.
In the past 5 years XGN always reported negative operating cash flow.
XGN Yearly Net Income VS EBIT VS OCF VS FCFXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

XGN's Return On Assets of -30.31% is fine compared to the rest of the industry. XGN outperforms 67.36% of its industry peers.
XGN has a Return On Equity (-104.97%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -30.31%
ROE -104.97%
ROIC N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
XGN Yearly ROA, ROE, ROICXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

XGN has a Gross Margin of 59.86%. This is in the better half of the industry: XGN outperforms 78.11% of its industry peers.
In the last couple of years the Gross Margin of XGN has grown nicely.
XGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
XGN Yearly Profit, Operating, Gross MarginsXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XGN has more shares outstanding
XGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XGN has a worse debt to assets ratio.
XGN Yearly Shares OutstandingXGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
XGN Yearly Total Debt VS Total AssetsXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.95, we must say that XGN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XGN (-3.95) is comparable to the rest of the industry.
XGN has a Debt/Equity ratio of 1.35. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.35, XGN is not doing good in the industry: 76.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Altman-Z -3.95
ROIC/WACCN/A
WACC8.8%
XGN Yearly LT Debt VS Equity VS FCFXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 4.08 indicates that XGN has no problem at all paying its short term obligations.
XGN has a Current ratio (4.08) which is in line with its industry peers.
A Quick Ratio of 4.08 indicates that XGN has no problem at all paying its short term obligations.
XGN has a Quick ratio (4.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
XGN Yearly Current Assets VS Current LiabilitesXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

XGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.74%.
The Revenue has grown by 14.08% in the past year. This is quite good.
The Revenue has been growing slightly by 6.62% on average over the past years.
EPS 1Y (TTM)5.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.71%
Revenue 1Y (TTM)14.08%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%37.87%

3.2 Future

The Earnings Per Share is expected to grow by 15.70% on average over the next years. This is quite good.
Based on estimates for the next years, XGN will show a quite strong growth in Revenue. The Revenue will grow by 14.02% on average per year.
EPS Next Y-5.72%
EPS Next 2Y19.5%
EPS Next 3Y16.77%
EPS Next 5Y15.7%
Revenue Next Year20.35%
Revenue Next 2Y17.96%
Revenue Next 3Y16.44%
Revenue Next 5Y14.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XGN Yearly Revenue VS EstimatesXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
XGN Yearly EPS VS EstimatesXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XGN Price Earnings VS Forward Price EarningsXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XGN Per share dataXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as XGN's earnings are expected to grow with 16.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.5%
EPS Next 3Y16.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

EXAGEN INC

NASDAQ:XGN (1/5/2026, 8:00:02 PM)

After market: 5.95 0 (0%)

5.95

-0.09 (-1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners48.54%
Inst Owner Change0%
Ins Owners3.15%
Ins Owner Change-3.17%
Market Cap134.83M
Revenue(TTM)63.60M
Net Income(TTM)-19.04M
Analysts83.33
Price Target15.74 (164.54%)
Short Float %5.12%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-60.42%
Min EPS beat(2)-94.88%
Max EPS beat(2)-25.97%
EPS beat(4)2
Avg EPS beat(4)-23.8%
Min EPS beat(4)-94.88%
Max EPS beat(4)23.84%
EPS beat(8)6
Avg EPS beat(8)5.06%
EPS beat(12)9
Avg EPS beat(12)11.35%
EPS beat(16)12
Avg EPS beat(16)9.72%
Revenue beat(2)2
Avg Revenue beat(2)2.77%
Min Revenue beat(2)1.05%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)2.17%
Min Revenue beat(4)-2.37%
Max Revenue beat(4)5.51%
Revenue beat(8)6
Avg Revenue beat(8)5.05%
Revenue beat(12)10
Avg Revenue beat(12)13.51%
Revenue beat(16)13
Avg Revenue beat(16)12.1%
PT rev (1m)0%
PT rev (3m)31.71%
EPS NQ rev (1m)-4.9%
EPS NQ rev (3m)-53.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.42%
Revenue NQ rev (1m)-1.22%
Revenue NQ rev (3m)-3.54%
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)-0.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.12
P/FCF N/A
P/OCF N/A
P/B 7.43
P/tB 7.43
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS2.81
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.31%
ROE -104.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.86%
FCFM N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
F-Score5
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.44%
Cap/Sales 1.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z -3.95
F-Score5
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)115%
Cap/Depr(5y)136.67%
Cap/Sales(3y)3.99%
Cap/Sales(5y)3.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.71%
EPS Next Y-5.72%
EPS Next 2Y19.5%
EPS Next 3Y16.77%
EPS Next 5Y15.7%
Revenue 1Y (TTM)14.08%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%37.87%
Revenue Next Year20.35%
Revenue Next 2Y17.96%
Revenue Next 3Y16.44%
Revenue Next 5Y14.02%
EBIT growth 1Y18.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.1%
EBIT Next 3Y33.14%
EBIT Next 5Y23.85%
FCF growth 1Y62.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.09%
OCF growth 3YN/A
OCF growth 5YN/A

EXAGEN INC / XGN FAQ

Can you provide the ChartMill fundamental rating for EXAGEN INC?

ChartMill assigns a fundamental rating of 2 / 10 to XGN.


What is the valuation status for XGN stock?

ChartMill assigns a valuation rating of 0 / 10 to EXAGEN INC (XGN). This can be considered as Overvalued.


How profitable is EXAGEN INC (XGN) stock?

EXAGEN INC (XGN) has a profitability rating of 2 / 10.


What is the earnings growth outlook for EXAGEN INC?

The Earnings per Share (EPS) of EXAGEN INC (XGN) is expected to decline by -5.72% in the next year.